Local carboplatin therapy in transgenic murine retinoblastoma

被引:0
作者
Harbour, JW
Murray, TG
Hamasaki, D
Cicciarelli, N
Hernandez, E
Smith, B
Windle, J
OBrien, JM
机构
[1] UNIV MIAMI,SCH MED,BASCOM PALMER EYE INST,DEPT OPHTHALMOL,MIAMI,FL 33101
[2] UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143
[3] SAN ANTONIO CANC CTR,SAN ANTONIO,TX
关键词
carboplatin; chemotherapy; retinoblastoma; toxicity studies; transgenic animal models;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To determine the efficacy and toxicity associated with intraocular delivery of carboplatin in the treatment of murine transgenic hereditary retinoblastoma. Methods, Forty-eight transgenic BLH-SV40 T ag retinoblastoma mice were administered five intravitreal injections of carboplatin in one eye. After 12 weeks, the eves were examined histopathologically to evaluate tumor burden. Twelve rabbits were administered intravitreal injections of carboplatin in one eye, after which they underwent serial electroretinography. All experimental and control eyes were obtained for histopathology and electron microscopy. Results. A dose-dependent inhibition of intraocular tumor growth by carboplatin was observed in transgenic retinoblastoma mice. Tumor development was inhibited in 50% of the mouse eyes at doses of 1.4 mu g. Ln rabbits, retinal toxicity resulted when intravitreal injections of carboplatin were administered at doses of 10 mu g or higher. Conclusions. Local delivery of carboplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent manner in transgenic murine retinoblastoma.
引用
收藏
页码:1892 / 1898
页数:7
相关论文
共 51 条
  • [1] ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351
  • [2] PILOT-STUDY OF SEQUENTIAL COMBINATION CHEMOTHERAPY IN ADVANCED AND RECURRENT RETINOBLASTOMA
    ADVANI, SH
    RAO, SR
    IYER, RS
    PAI, SK
    KURKURE, PA
    NAIR, CN
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 22 (02): : 125 - 128
  • [3] AKIYAMA K, 1988, OPHTHALMIC GENET, V10, P111
  • [4] ALBERT DM, 1992, INVEST OPHTH VIS SCI, V33, P2354
  • [5] ALLEN JC, 1994, CANCER, V74, P940, DOI 10.1002/1097-0142(19940801)74:3<940::AID-CNCR2820740323>3.0.CO
  • [6] 2-U
  • [7] CALVERT H, 1993, CANCER SURV, V17, P189
  • [8] Char DH, 1989, CLIN OCULAR ONCOLOGY
  • [9] DOZ F, 1994, CANCER, V74, P722, DOI 10.1002/1097-0142(19940715)74:2<722::AID-CNCR2820740228>3.0.CO
  • [10] 2-H